Cost-effectiveness analysis of CYP2C19 genotype-guided antiplatelet therapy for patients with acute minor ischemic stroke and high-risk transient ischemic attack in China.

Zhang, Zhuolin; Bao, Yuwen; Gu, Yajie; Zhang, Mengdie; Li, Xin

Zhang, Zhuolin; Bao, Yuwen; Gu, Yajie; Zhang, Mengdie; Li, Xin.

Zhang Z; School of Pharmacy, Nanjing Medical University, Nanjing, China.
Bao Y; School of Health Policy and Management, Nanjing Medical University, Nanjing, China.
Gu Y; School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
Zhang M; School of Pharmacy, Nanjing Medical University, Nanjing, China.
Li X; School of Pharmacy, Nanjing Medical University, Nanjing, China.

Br J Clin Pharmacol ; 90(2): 483-492, 2024 02.

Article en En | MEDLINE | ID: mdl-37795861

Asunto(s)

Ataque Isquémico Transitorio; Accidente Cerebrovascular Isquémico; Accidente Cerebrovascular; Humanos; Inhibidores de Agregación Plaquetaria/uso terapéutico; Clopidogrel/uso terapéutico; Ticagrelor/uso terapéutico; Ataque Isquémico Transitorio/tratamiento farmacológico; Citocromo P-450 CYP2C19/genética; Accidente Cerebrovascular Isquémico/inducido químicamente; Accidente Cerebrovascular Isquémico/tratamiento farmacológico; Análisis de Costo-Efectividad; Cilostazol; Análisis Costo-Beneficio; Genotipo; Accidente Cerebrovascular/tratamiento farmacológico; Accidente Cerebrovascular/inducido químicamente

Palabras clave

antiplatelet therapy; cilostazol; clopidogrel; cost-effectiveness analysis; cytochrome P450 2C19; ticagrelor

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Ataque Isquémico Transitorio / Accidente Cerebrovascular / Accidente Cerebrovascular Isquémico Tipo de estudio: Etiology_studies / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google